Literature DB >> 26438680

Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.

Jean Triscott1, Susan Mercer2, Peter George Jaminal Tian1, Bonnie Dobbs1.   

Abstract

An 81-year-old woman with chronic kidney disease was on enoxaparin (1 mg/kg subcutaneously two times a day) for 4 months to manage pulmonary embolism. While admitted for diagnostic evaluation of frequent falls, transient ischaemic attacks and pain management, she developed vomiting, diarrhoea, melena and hypotension. Her estimated glomerular filtration rate decreased from an admission value of 34 mL/min/1.73 m2 to 13 mL/min/1.73 m2. CT scan showed retroperitoneal haematoma. She was placed in intensive care and stabilised with aggressive fluid replacement, blood transfusion, and discontinuation of enoxaparin and concomitant aspirin. We attribute this major bleeding to enoxaparin use in an elderly woman with chronic kidney disease and concomitant aspirin intake. We will review reported cases of enoxaparin-associated retroperitoneal haematoma. We suggest that enoxaparin be used with caution in elderly patients with chronic kidney disease, and stress that treatment monitoring and reversal may not be readily available. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438680      PMCID: PMC4600799          DOI: 10.1136/bcr-2015-211699

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Guideline on the management of bleeding in patients on antithrombotic agents.

Authors:  Mike Makris; Joost J Van Veen; Campbell R Tait; Andrew D Mumford; Mike Laffan
Journal:  Br J Haematol       Date:  2012-11-01       Impact factor: 6.998

5.  Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey.

Authors:  Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi
Journal:  CMAJ       Date:  2013-05-06       Impact factor: 8.262

  5 in total
  1 in total

1.  Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department.

Authors:  Ignacio Novo-Veleiro; Lucía Alvela-Suárez; Alba Costa-Grille; Javier Suárez-Dono; Fernando Ferrón-Vidan; Antonio Pose-Reino
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.